Area residents are accustomed to seeing the Fred & Pamela Buffett Cancer Center name on Omaha's Midtown skyline, but it will soon appear in three additional locations.
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.